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ANTI-COAGULATION, ANTI-PLATELETS OR NO THERAPY IN 
HAEMODIALYSIS PATIENTS WITH ATRIAL FIBRILLATION: A DECISION 
ANALYSIS 
  
INTRODUCTION 
Atrial fibrillation (AF) is relatively common among maintenance haemodialysis patients with 
most studies reporting a prevalence of between 12% and 17%.(1-6) Haemodialysis patients 
with AF are at increased risk of ischemic stroke, thromboembolism,  hospitalisation and 
premature death as compared to those without AF.(7-9) 
 
The decision to anti-coagulate or use anti-platelet therapy in a patient with AF requires 
consideration of potential risks versus benefits. Such risks and benefits have been established 
for the general population through multiple large randomised controlled trials (RCTs).(10-12) 
These data have been used to power predictive scores,the CHADS2  (Cardiac failure, 
Hypertension, Age, Diabetes and Stroke) score and more recently the CHA2DS2-VASc 
(Cardiac failure, Hypertension, Age, Diabetes, Stroke, Vascular disease and gender) scores, 
which use patient risk factors to estimate stroke risk and guide treatment decisions in the 
general population.(13, 14) Patients with impaired kidney function were excluded from these 
trials, and it is not certain whether or not their findings are applicable to the haemodialysis 
population. Haemodialysis patients have a different risk-benefit profile for anti-coagulation 
and anti-platelet agents than the general population due to factors including platelet 
dysfunction from uraemia, altered pharmacokinetics and increased falls risk.(15, 16) There 
are also concerns that the use of warfarin in haemodialysis patients may increase vascular 
calcification and hence, ischemic stroke risk.(15, 17) 
  
No RCTs of anti-coagulation or anti-platelet interventions in haemodialysis patients with AF 
have been conducted. Thus, the evidence base consists largely of small observational studies 
reporting conflicting results.(2, 3, 7, 8, 18-20) Informed clinical decision-making is 
challenging in the face of this inadequate evidence base and there is considerable controversy 
over when, and if, anti-coagulation and anti-platelet therapy should be used in the 
haemodialysis population. 
 
The aim of this study was to incorporate the most recent evidence into a decision analysis 
offering an up to date perspective of the treatment of AF in haemodialysis patients. It seeks to 
answer the question: Does warfarin offer superior Quality Adjusted Life Years (QALYs) to 
aspirin and/or no anti-thrombotic therapy in haemodialysis patients with AF? 
 
METHODS 
We constructed a Markov model using decision analytic software (TreeAge Pro 2012, 
Williamstown, USA) to compare the benefits of anti-coagulation (warfarin), anti-platelet 
agents (aspirin) and no therapy in haemodialysis patients with AF. Our base case was a 72 
year old man on haemodialysis with non-valvular AF, reflecting the mean age of patients on 
haemodialysis with AF in the literature.(1, 6, 7, 18, 21)  
 
Markov model design 
Markov models represent the natural history of a disease and use hypothetical patients with 
disease courses that reflect those found in the literature. Disease courses are characterised by 
predefined mutually exclusive health states. Patients transition between these states in each 
‘Markov cycle’ according to probabilities drawn from the literature.(22) Expected outcomes 
per hypothetical patient are determined by summing all the expected costs and benefits in 
each health state that the patient experiences.(22) 
 
Our model followed 1000 hypothetical patients split into three cohorts by treatment option 
(warfarin, aspirin, no therapy). We built the model to run 3 monthly Markov cycles for 20 
cycles (five years). The time horizon reflects the older age of haemodialysis patients with AF, 
the chronic nature of the disease and its life-long complications. The structure of our model 
and the health states are outlined in Figure 1. 
 
Clinical data and health outcomes 
We performed a comprehensive literature search to determine the best available estimates for 
clinical data and health outcomes. The search strategy is outlined in Appendix 1.  
 
The clinical data included transition probabilities (the probability of transitioning between 
health states) and the relative risks of transitioning between health states on different 
treatments (see Table 1). Where there were multiple sources of probabilities or relative risks 
these were meta-analysed in Stata software version 12 (StataCorp, College Station, Texas 
USA).  
 
We measured health outcomes by life years and QALYs. QALYs are used in economic 
evaluations because they incorporate both the expected number of years lived as well as the 
quality of life (measured in utilities) during those years. Preference based utilities on a 0-1 
scale where 0 is death and 1 is full health were preferred (e.g. EQ-5D, time trade off, and 
standard gamble).(22) Where utilities specific to patients on haemodialysis with AF were not 
available, utilities from the general population were used. Health states required the use of 
multiple utilities (e.g. a hypothetical patient on haemodialysis with AF taking warfarin and 
who suffered a stroke). To create these utilities we used the haemodialysis utility as our base 
and then created disutilities that were each subtracted from the base case. Disutilities captured 
all aspects of treatment, including requirements to take medication and undergo monitoring in 
addition to side-effects such as bleeding. All outcomes were discounted at an annual rate of 
5% which is a standard practice in economic evaluations.(23)  
 
For both clinical and health outcomes we determined plausible ranges for each probability or 
relative risk to be the 95% confidence interval calculated in our meta-analysis, the published 
95% confidence interval when only one published study was used, or half and double the 
probability (i.e. using a standard multiplier formula) if a confidence interval was not 
available. 
 
Model assumptions 
We made the following assumptions in constructing our Markov model: 1) the outcomes of 
ischemic and haemorrhagic strokes were the same; 2) stroke outcomes of haemodialysis 
patients (i.e. the probability of disability or death) with AF were the same as patients in the 
general population with AF; 3) the relative risk of haemorrhagic stroke in patients on aspirin 
versus no therapy was 1; 4) the anti-coagulation and anti-platelet agents of patients who 
experienced either a haemorrhagic stroke or an extracranial bleed were immediately and 
permanently ceased; 5) the disutility associated with AF, warfarin use, aspirin use, and stroke 
outcomes were the same in haemodialysis patients as in the general population. 
 
Sensitivity analyses 
We conducted multiple sensitivity analyses to determine the impact of uncertainty on model 
results. One-way sensitivity analyses were performed on each variable over the range 
specified in Table 1 while holding all other variables constant. Unless otherwise specified, the 
range represented the highest and lowest values we identified in the literature. We further 
investigated the key variables of extracranial bleeding, haemorrhagic stroke and ischemic 
stroke by two-way sensitivity analyses for warfarin, aspirin and no therapy. This was done by 
simultaneously varying both stroke rates and bleeding rates for each treatment type over the 
range specified in Table 1. 
 
Probabilistic sensitivity analysis enabled us to evaluate the impact of uncertainty across all 
key parameters simultaneously and so provide a more accurate estimate of outcomes. To 
perform this analysis we modelled our input variables as distributions following standard 
methods.(24) The probabilities of moving between health states and the utilities were 
modelled as beta distributions (bounded by 0 and 1), while the relative risks (of warfarin and 
aspirin versus no therapy) were modelled as log-normal distributions and 500,000 monte 
carlo simulations were conducted.(24)  
 
RESULTS 
The clinical data and utilities used in the model are presented in Tables 1 and 2. 
Base-case analysis. The mean life expectancy of a 72 year old man on haemodialysis and 
with AF was 9.55 cycles (2.39 years) treated with warfarin, 9.59 cycles (2.40 years) with 
aspirin, and 9.58 cycles (2.39 years) with no therapy. Incorporating quality of life led to a 
mean QALY of 5.94 cycles (1.49 years) treated with warfarin, 6.47 cycles (1.62 years) with 
aspirin, and 6.48 cycles (1.62 years) with no therapy. Thus, warfarin led to 0.14 fewer 
QALYs or 1.6 fewer months of life lived in full health, than either aspirin or no therapy (see 
Table 3). 
 
One-way sensitivity analyses. The base case was only sensitive to the relative risk of death 
from other (non stroke, non bleed) causes as shown in Table 4. 
 
Two-way sensitivity analyses. ‘No therapy’ was the preferred treatment strategy under all 
scenarios. 
 
Probabilistic sensitivity analyses. The mean life expectancy for the base case via 
probabilistic sensitivity analysis was 2.39 years for no therapy, 2.40 years for aspirin and 2.39 
years for warfarin. For the outcome of life expectancy 77% of simulations favoured aspirin, 
18% of simulations favoured no therapy and 5% of simulations favoured warfarin. The mean 
QALYs for the base case via probabilistic sensitivity analysis were 1.62 years for no therapy, 
1.62 years for aspirin and 1.48 years for warfarin. For the outcome of quality-adjusted life 
expectancy, 60% of simulations favoured aspirin, 40% of simulations favoured no therapy 
and 0.2% of simulations favoured warfarin. In summary, in 95% of simulations for survival 
and 99.8% of simulations for QALYs, warfarin was not the preferred treatment choice for AF 
in haemodialysis patients given the current evidence base in the literature. 
 
DISCUSSION 
We found that for our base case patient, a 72 year old male haemodialysis patient with atrial 
fibrillation there was no difference in life expectancy between warfarin, aspirin and no 
treatment but that warfarin provided 1.6 fewer months lived in full health. The one-way, two-
way and probabilistic sensitivity analyses did not alter the base case findings.  
 
Our results suggest that the decision to use warfarin in a haemodialysis patient with AF 
should be considered very carefully and that for patients that resemble our base case patient, a 
72 year old man, warfarin may not be the preferred treatment option. We caution that our 
findings cannot be applied to patients that differ from this base case, e.g. are much younger, 
and note that the difference between each treatment option, warfarin, aspirin and no therapy is 
small and is overshadowed by the poor prognosis of these patients regardless of anti-
coagulation / anti-platelet therapy. 
 
A decision analysis has been previously conducted by Quinn et al.(25) They found that 
warfarin produced an additional 0.1 years of life expectancy and an additional 0.09 years of 
QALY versus no therapy and was superior to both no therapy and aspirin.(25) Since this 
publication, a number of important studies looking at stroke and bleeding rates in 
haemodialysis patients with AF patients have been published, and these are incorporated into 
our transition probabilities which consequently differ from Quinn et al’s.(26-28) 
 
The strengths of this paper include its use of the most current evidence available, that it draws 
utilities from all possible sources, both directly measured and transformed from SF-36 data, 
and our use of sensitivity analysis, particularly probabilistic sensitivity analysis. However, the 
study also has several limitations. First, the evidence base underpinning the decision analysis 
is limited to retrospective, observational studies of small patient populations and where AF 
may not have been the primary indication for warfarin use. Second, we could not adequately 
account for demographic differences such as age and sex, nor for clinical differences such as 
comorbidities, because of the incompleteness of reported data and our reliance on the 
aggregated, rather than patient-level, data provided by published studies. Third, we had to use 
some data (such as stroke outcomes) that were not drawn from the haemodialysis population.  
 
Areas for further research include large well-designed epidemiological studies and, crucially, 
a prospective RCT where haemodialysis patients with AF are randomised to receive warfarin, 
aspirin, or placebo. Large epidemiological studies are needed to ensure that the RCT draws 
from the right patient subsets and so provides clinically meaningful results to guide treatment 
decisions. 
 
CONCLUSIONS 
Our results suggest that warfarin should not be the default choice for haemodialysis patients 
with non-valvular AF. We found that warfarin provided the fewest QALYs compared to 
aspirin and no therapy. However, we note that the evidence base underpinning our decision 
analysis is sub-optimal and further research is required to definitively delineate the role, if 
any, of anti-coagulation and anti-platelet agents in haemodialysis patients with AF. 
  
 Appendix 1: Search strategy 
The literature search was conducted in Medline, EMBASE and the Cochrane Database of 
Systematic Reviews from database inception until October 2012 and through a manual search 
of the reference lists from relevant studies.  For transition probabilities and relative risks we 
used the following text words or medical subject headings (MeSH): “atrial fibrillation” plus 
one or more of “renal failure”, “kidney failure”, “end stage kidney disease”, “end stage renal 
disease”, “end stage kidney failure”, “end stage renal failure”, “dialysis”, “haemodialysis”, 
“hemodialysis”. For utilities we added the text words “utility” or “utilities” or “quality of life” 
and MeSH heading “quality-adjusted life years”. 
 
Randomised controlled trials, observational series, case series and population-based registry 
studies were all included. We excluded review articles, comments, editorials, letters and case 
reports.  
 
Figure 1: Model structure showing health states Patients enter the model on haemodialysis 
(HD) and with AF. During each 3 monthly cycle patients can either remain in their current 
state (recursive arrow) or progress to a new health state (straight arrow).  
 
 
  
Table 1: Clinical data 
Variable Base case Low High Sources 
Probabilities per 3 month cycle     
Ischemic stroke rate – No therapy 0.006 0.004 0.009 (19) 
Haemorrhagic stroke rate – No therapy 0.0013 0.0005 0.0035 (19) 
Major bleed – No therapy 0.002 0.00* 0.07 (27, 28) 
Death from other causes 0.07 0.03* 0.17* (19) 
Outcome probabilities     
Stroke – Recover 0.22 0.11* 0.43* (29) 
Stroke – Mild disability 0.30 0.15* 0.60* (29) 
Stroke – Severe disability 0.23 0.12* 0.46* (29) 
Stroke – Death  0.26 0.19 0.47 (29-31) 
Major bleed - Death 0.13 0.07* 0.26* (19) 
Relative risks     
Ischemic stroke – Warfarin 0.94 0.72 1.22 (19, 26, 32) 
Ischemic stroke – Aspirin 0.92 0.67 1.26 (19, 26) 
Haemorrhagic stroke - Warfarin 2.31 1.35 3.94 (19, 32) 
Haemorrhagic stroke - Aspirin 1.00 0.50* 2.00*  
Major bleed - Warfarin 3.88 1.5 67.2 (19, 28, 33) 
Major bleed - Aspirin 5.50 2.75* 20 (28, 33) 
Death from other causes - Warfarin 1.03 .052* 2.06* (19) 
Death from other causes - Aspirin 1.00 0.50* 2.00* (19) 
* Estimates where a broad range of probabilities were not available in the literature. Estimates 
are for half the base case for the low end and double the base case for the high end.  
 
 
  
Table 2: Utilities 
Utilities Base case Low High Sources 
Utility of haemodialysis patients 0.69 0.59 0.80 (34) 
Disutility from AF 0 0 -0.15 (35, 36) 
Disutility from taking warfarin -0.05 -0.06 -0.01 (37, 38) 
Disutility from taking aspirin -0.002 -0.006 0 (37) 
Disutility from minor disability 
following a stroke 
-0.24 -0.42 -0.05 (38-42) 
Disutility from severe disability 
following a stroke 
-0.62 -0.81 -0.44 (39-42) 
Disutility from surviving a major 
bleed 
0.16 0.32* 0.08* (38) 
Death 0 0 0 Definitional 
* Estimates where a broad range of probabilities were not available in the literature. Estimates 
are for half the base case for the low end and double the base case for the high end.  
 
Table 3: Life expectancy and quality-adjusted life expectancy for each of the four 
treatment options  
AF treatment Life expectancy 
(years)* 
Incremental 
life expectancy 
QALY* Incremental 
QALY 
No therapy 2.39  1.62  
Aspirin 2.40 +0.01 1.62  0.00 
Warfarin 2.39   0.00 1.49 -0.14 
 
*All outcomes are discounted 
  
Table 4: Influential variables from one-way sensitivity analyses 
Variable Threshold Comments 
Relative risk of death from 
other causes while treated with 
warfarin 
0.83 Warfarin is the preferred treatment option 
when the relative risk of death from causes 
unrelated to stroke or bleeding is below 0.83 
(compared to no therapy) 
Relative risk of death from 
other causes while treated with 
aspirin 
1.01 Aspirin is the preferred treatment option when 
the relative risk of death from causes unrelated 
to stroke or bleeding is below 1.01 (compared 
to no therapy) 
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